Cyclo Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.19) Estimate, Sales $202.450K Miss $376.667K Estimate

5/16/24 8:29:24 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CYTH alert in real time by email

Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.19) by 21.05 percent. The company reported quarterly sales of $202.450 thousand which missed the analyst consensus estimate of $376.667 thousand by 46.25 percent. This is a 32.83 percent increase over sales of $152.411 thousand the same period last year.

Get the next $CYTH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CYTH

Date	Price Target	Rating	Analyst

More analyst ratings

$CYTH
Press Releases

Fastest customizable press release news feed in the world

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseeing all aspects of the company's financial operations. "We are delighted to welcome Shawn as our new Chief Financial Officer and look forward to his leadership and guidance as we invest in long-term growth and value creation while maintaining high standards in resource allocation and execution," said Frank D. Lee, chief executive officer of Pacira BioSciences. "Shawn brings a strong set of experienc
10/21/24 8:00:00 AM ET
$CYTH
$PCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1 Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 Trappsol® Cyclo™ demonstrated to be well tolerated in ongoing substudy with a safety profile consistent with that of completed phases Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines
9/5/24 9:05:00 AM ET
$CYTH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common
8/22/24 6:50:00 AM ET
$CYTH
$RFL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Real Estate
Finance

$CYTH
Leadership Updates

Live Leadership Updates

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common
8/22/24 6:50:00 AM ET
$CYTH
$RFL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Real Estate
Finance
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio
8/22/24 6:50:00 AM ET
$CYTH
$RFL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Real Estate
Finance
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
– Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 study, TransportNPC™ – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC and demonstrate acceptable safety profile of Trappsol® Cyclo™ administered intravenously for more than 2 years Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-cha
12/9/21 8:05:00 AM ET
$CYTH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Cyclo Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.19) Estimate, Sales $202.450K Miss $376.667K Estimate

Chat with this insight

Recent Analyst Ratings for
$CYTH

$CYTH
Market Insights

Live Market Insights

Cyclo Therapeutics Has Been Granted European Patent Number EP3873604 Titled "METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN"

HC Wainwright & Co. Reiterates Buy on Cyclo Therapeutics, Maintains $3 Price Target

Cyclo Therapeutics Completes Last Patient In Phase 3 TransportNPC Trial Of Niemann-Pick Type C1

$CYTH
Press Releases

Fastest customizable press release news feed in the world

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

$CYTH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

SEC Form SC 13G filed by Cyclo Therapeutics Inc.

$CYTH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Shanahan William S was granted 7,937 shares, increasing direct ownership by 6% to 133,681 units (SEC Form 4)

Director Conkling William was granted 8,731 shares, increasing direct ownership by 35% to 33,570 units (SEC Form 4)

Director Cross Shawn was granted 9,028 shares, increasing direct ownership by 11% to 90,521 units (SEC Form 4)

$CYTH
Leadership Updates

Live Leadership Updates

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease

$CYTH
SEC Filings

Cyclo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$CYTH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

Cyclo Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.19) Estimate, Sales $202.450K Miss $376.667K Estimate

Chat with this insight

Recent Analyst Ratings for $CYTH

$CYTH Market Insights

Live Market Insights

Cyclo Therapeutics Has Been Granted European Patent Number EP3873604 Titled "METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN"

HC Wainwright & Co. Reiterates Buy on Cyclo Therapeutics, Maintains $3 Price Target

Cyclo Therapeutics Completes Last Patient In Phase 3 TransportNPC Trial Of Niemann-Pick Type C1

$CYTH Press Releases

Fastest customizable press release news feed in the world

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

$CYTH Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

SEC Form SC 13G filed by Cyclo Therapeutics Inc.

$CYTH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Shanahan William S was granted 7,937 shares, increasing direct ownership by 6% to 133,681 units (SEC Form 4)

Director Conkling William was granted 8,731 shares, increasing direct ownership by 35% to 33,570 units (SEC Form 4)

Director Cross Shawn was granted 9,028 shares, increasing direct ownership by 11% to 90,521 units (SEC Form 4)

$CYTH Leadership Updates

Live Leadership Updates

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease

$CYTH SEC Filings

Cyclo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$CYTH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

Recent Analyst Ratings for
$CYTH

$CYTH
Market Insights

$CYTH
Press Releases

$CYTH
Large Ownership Changes

$CYTH
Insider Trading

$CYTH
Leadership Updates

$CYTH
SEC Filings

$CYTH
Analyst Ratings